Diabetes Drug Reduces Heart Failure Risk in Cancer Patients by 50% – A Game-Changer for Recovery
A widely used diabetes medication, SGLT2 inhibitors, has shown a surprising benefit for cancer patients—protecting their ...
AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients
AstraZeneca's Imfinzi perioperative regimen improved event-free survival in gastric and GEJ cancer. The trial showed a strong ...
CURE2d
Imfinzi Plus Chemo May Improve Event-Free Survival in Gastric, GEJ Cancers
Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...
MPR3d
Tevimbra Plus Chemotherapy Approved as First-Line Tx for Advanced Esophageal Cancer
The Food and Drug Administration (FDA) has approved Tevimbra® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the ...
Medical News Today12d
Everything you need to know about oral chemotherapy
Oral chemotherapy kills or weakens cancer cells. It comes in the form of a pill, liquid, or tablet that a person swallows or places under the tongue to dissolve. It is not suitable for all stages ...
MPR2d
Durvalumab Plus FLOT Improves Event Free Survival in Gastric/GEJ Cancer
Topline results were announced from a phase 3 trial evaluating durvalumab in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) ...
Cantargia's TRIFOUR Phase 2 Study Investigating Nadunolimab in Triple Negative Breast Cancer Fully Recruited
TRIFOUR is Cantargia's first randomized, controlled study of nadunolimabFirst preliminary efficacy results expected mid-2025 LUND, SWEDEN / ACCESS Newswire / March 10, 2025 / Cantargia (Cantargia AB); ...